Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 4/20 | 0.36 |
| ▸ | TYK2 | P29597 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 6/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18246168 | 1.00 | NOS1 (0.38) | NOS1JAK2JAK1TYK2JAK3 | |
| SCHEMBL18246269 | 1.00 | NOS1 (0.38) | NOS1JAK2JAK1TYK2JAK3 | |
| SCHEMBL18245797 | 1.00 | NOS1 (0.38) | NOS1JAK2JAK1TYK2JAK3 | |
| SCHEMBL28456407 | 1.00 | NOS1 (0.38) | NOS1JAK2JAK1TYK2JAK3 | |
| SCHEMBL15703055 | 0.83 | NOS1 (0.36) | NOS1APLNRACHETDO2 | |
| SCHEMBL21767182 | 0.80 | NOS1 (0.33) | NOS1ACHE | |
| SCHEMBL17476841 | 0.79 | JAK2 (0.36) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL17480827 | 0.79 | JAK2 (0.36) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL17476836 | 0.79 | JAK2 (0.36) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL179278 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3300500-B9 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-108137545-B | Triazole agonists of the APJ receptor | 美国安进公司 | 2020-09-22 | — | — | CN | disclosed |
| EP-3300500-B1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221162-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221162-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180319773-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| WO-2016187308-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187308-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319773-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | NOS1 2930/4885JAK2 676/4885JAK1 559/4885 |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | APH1A, BRDT, APH1B | NOS1 4631/4885JAK2 4069/4885JAK1 4798/4885 |
| US-10344016-B2 | Bromotriazole intermediates | APH1A, BRDT, APH1B | NOS1 4631/4885JAK2 4069/4885JAK1 4798/4885 |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | NOS1 2930/4885JAK2 676/4885JAK1 559/4885 |
| US-10221162-B2 | Triazole agonists of the APJ receptor | TBXA2R, AGTR1, AGTR2 | NOS1 2930/4885JAK2 676/4885JAK1 559/4885 |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | NOS1 2930/4885JAK2 676/4885JAK1 559/4885 |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | NOS1 2930/4885JAK2 676/4885JAK1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.